Systemic therapy of New World cutaneous leishmaniasis: A case report and review article

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 21, Issue 2, 2010, Pages

  Abadir, Amir ^a   Patel, Ameen ^a   Haider, Shariq ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Cutaneous leishmaniasis; Itraconazole; Leishmania panamensis; PCR; Stibogluconate

Indexed keywords

ITRACONAZOLE; STIBOGLUCONATE SODIUM;

AGED; CASE REPORT; COSTA RICA; DRUG TREATMENT FAILURE; HUMAN; LEISHMANIA PANAMENSIS; MALE; POLYMERASE CHAIN REACTION; REVIEW; SKIN BIOPSY; SKIN LEISHMANIASIS; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 77953645691     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2010/768645     Document Type: Review

References (20)

1. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous leishmaniasis. Lancet Infect Dis 2007;7:581-96.
2. Schwartz E, Hatz C, Blum J. New world cutaneous leishmaniasis in travellers. Lancet Infect Dis 2006;6:342-9.
3. Statistics Canada 〈http://www40.statcan.gc.ca/l01/cst01/arts37aeng. htm〉 (Accessed on July 22, 2009).
4. Lawn SD, Whetham J, Chiodini PL, et al. New world mucosal and cutaneous leishmaniasis: An emerging health problem among British travellers. QJM 2004;97:781-8.
5. Zeegelaar JE, Steketee WH, van Thiel PP, Wetsteyn JC, Kager PA, Faber WR. Changing pattern of imported cutaneous leishmaniasis in the Netherlands. Clin Exp Dermatol 2005;30:1-5.
6. Beyrer C, Villar JC, Suwanvanichkij V, Singh S, Baral SD, Mills EJ. Neglected diseases, civil conflicts, and the right to health. Lancet 2007;370:619-27.
7. Freedman DO, Weld LH, Kozarsky PE, et al. Spectrum of disease and relation to place of exposure among ill returned travellers. New Engl J Med 2006;354:119-30.
8. Herwaldt BL. Leishmaniasis. Lancet 1999;354:1191-9.
9. Berman JD. Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997;24:684-703.
10. Soto J, Arana BA, Toledo J, et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 2004;38:1266-72. (Pubitemid 38608569)
11. Ouellette M, Drummelsmith J, Papadopoulou B. Leishmaniasis: Drugs in the clinic, resistance and new developments. Drug Resist Updat 2004;7:257-66. (Pubitemid 39469098)
12. Templeton HJ. Cutaneous leishmaniasis, experimentally produced. Cal West Med 1941;54:70-1.
13. Tuon FF, Amato VS, Graf ME, Siqueira AM, Nicodemo AC, Neto VA. Treatment of new world cutaneous leishmaniasis - a systematic review with a meta-analysis. Int J Dermatol 2008;47:109-24.
14. Berman JD, Waddell D, Hanson BD. Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate. Antimicrob Agents Chemother 1985;27:916-20.
15. Wyllie S, Cunningham ML, Fairlamb AH. Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J Biol Chem 2004;279:39925-32.
16. Pathak MK, Yi T. Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. J Immunol 2001;167:3391-7. (Pubitemid 32852583)
17. Aronson NE, Wortmann GW, Johnson SC, et al. Safety and efficacy of sodium stibogluconate in the treatment of leishmaniasis: Recent U.S. military experience. Clin Infect Dis 1998;27:1457-64.
18. Chulay JC, Spencer HC, Mugambi M. Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony (sodium stibogluconate). Am J Trop Med Hyg 1985;43:702-9. (Pubitemid 16237013)
19. Gonzalez U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed JA. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev 2009;2:CD004834.
20. Chokshi DA, Rajkumar R. Leveraging university research to advance global health. JAMA 2007;298:1934-6. (Pubitemid 350005239)